Management of dry mouth: assessment of oral symptoms after use of a polysaccharide-based oral rinse

Published:September 27, 2016DOI:


      Salivary dysfunction is associated with a range of oral/dental issues, and management of oral symptoms may improve oral function and overall quality of life. The purpose of this pilot study was to evaluate oral symptoms and function in a xerostomic population after use of a proprietary topical for dry mouth, Moisyn (Synedgen Inc., Claremont, CA), which is a polysaccharide-based product.

      Study Design

      A pre- and post-test survey was completed by 57 patients with xerostomia. Patients rated their common oral symptoms, based on the Vanderbilt Head and Neck Symptom Survey, before and after 1-week use of Moisyn rinse and spray. Saliva production under resting and chewing stimulation was also assessed.


      Most patients reported relief from dry mouth symptoms and thick saliva (81.7% and 76.0%, respectively) for more than 30 minutes after product use. Statistically significant reductions were found in 15 of 33 oral symptoms. Symptom improvement ranged from 10.7% to 28.4% for thick saliva, 8.4% to 30.6% for pain, 5.5% to 30.4% for dry mouth, and 12% to 21.3% for taste/diet change. Whole unstimulated/resting saliva improved by 100%, and whole stimulated saliva improved by 23.8%.


      These findings suggest that the product has utility in symptom control in patients with xerostomia and may lead to an increase in saliva production.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Sreebny L.M.
        Saliva in health and disease: an appraisal and update.
        Int Dent J. 2000; 50: 140-161
        • Amerongen A.V.
        • Veerman E.C.
        Saliva-the defender of the oral cavity.
        Oral Dis. 2002; 8: 12-22
        • Guggenheimer J.
        • Moore P.A.
        Xerostomia: etiology, recognition and treatment.
        J Am Dent Assoc. 2003; 134: 61-69
        • Atkinson J.C.
        • Baum B.J.
        Salivary enhancement: current status and future therapies.
        J Dent Educ. 2001; 65: 1096-1101
        • Ship J.A.
        • Mccutcheon J.A.
        • Spivacovsky S.
        • Kerr A.R.
        Safety and effectiveness of topical dry mouth products containing olive oil, betaine, and xylitol in reducing xerostomia for polypharmacy-induced dry mouth.
        J Oral Rehabil. 2007; 34: 724-732
        • Sreebny L.M.
        Dry mouth: a multifaceted diagnostic dilemma.
        in: Sreebny L.M. Vissink A. Dry Mouth—the Malevolent Symptom: A Clinical Guide. Wiley-Blackwell, Ames, IA2010: 33-51
        • Kolnick L.
        • Deng J.
        • Epstein J.B.
        • et al.
        Associations of oral health items of the Vanderbilt Head and Neck Symptom Survey with a dental health assessment.
        Oral Oncol. 2014; 50: 135-140
        • Fox P.C.
        • Busch K.A.
        • Baum B.J.
        Subjective reports of xerostomia and objective measures of salivary gland performance.
        J Am Dent Assoc. 1987; 115: 581-584
        • Bardow A.
        • Nyvad B.
        • Nauntofte B.
        Relationships between medication intake, complaints of dry mouth, salivary flow rate and composition, and the rate of tooth demineralization in situ.
        Arch Oral Biol. 2001; 46: 413-423
        • Singh M.L.
        • Papas A.
        Oral implications of polypharmacy in the elderly.
        Dent Clin North Am. 2014; 58: 783-796
        • Saleh J.
        • Figueiredo M.A.
        • Cherubini K.
        • et al.
        Salivary hypofunction: an update on aetiology, diagnosis and therapeutics.
        Arch Oral Biol. 2015; 60: 242-255
        • Cooperstein E.
        • Gilbert J.
        • Epstein J.B.
        • et al.
        Vanderbilt head and neck symptom survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health.
        Head Neck. 2012; 34: 797-804
        • Epstein J.B.
        • Villines D.
        • Sroussi H.
        Patient reported outcomes of the clinical use of a novel proprietary topical dry mouth product.
        Spec Care Dentist. 2015; 35: 197-204
        • Epstein J.B.
        • Beier Jensen S.
        Management of hyposalivation and xerostomia: criteria for treatment strategies.
        Compend Contin Educ Dent. 2015; 36: 600-603
        • Kerr A.R.
        • Katz R.W.
        • Ship J.A.
        A comparison of the effects of 2 commercially available nonprescription mouthrinses on salivary flow rates and xerostomia.
        Quintessence Int. 2007; 38: e440-e447
        • De Rossi S.S.
        • Thoppay J.
        • Dickinson D.P.
        • et al.
        A phase II clinical trial of a natural formulation containing tea catechins for xerostomia.
        Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 118: 447-454